Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) EPS (Basic) (2019 - 2025)

Eton Pharmaceuticals' EPS (Basic) history spans 7 years, with the latest figure at -$0.07 for Q3 2025.

  • For Q3 2025, EPS (Basic) fell 450.0% year-over-year to -$0.07; the TTM value through Sep 2025 reached -$0.25, down 13.64%, while the annual FY2024 figure was -$0.15, 275.0% down from the prior year.
  • EPS (Basic) for Q3 2025 was -$0.07 at Eton Pharmaceuticals, up from -$0.1 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $209.72 in Q2 2022 and bottomed at -$210.0 in Q1 2022.
  • The 5-year median for EPS (Basic) is -$0.06 (2025), against an average of -$0.04.
  • The largest YoY upside for EPS (Basic) was 233122.22% in 2022 against a maximum downside of 100100.0% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $0.04 in 2021, then increased by 0.0% to $0.04 in 2022, then crashed by 325.0% to -$0.09 in 2023, then skyrocketed by 77.78% to -$0.02 in 2024, then tumbled by 250.0% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for ETON's EPS (Basic) are -$0.07 (Q3 2025), -$0.1 (Q2 2025), and -$0.06 (Q1 2025).